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Purpose: To report a severe ocular complication initiated ten days after intravitreal 
administration of bevacizumab (Avastin®), in a patient with exudative age-related macular 
degeneration (AMD). 
Patients and method: Case report.
Results: Ten days after intravitreal injection of 1.25 mg Avastin®, the patient manifested acute 
loss of vision with excruciating pain. An extensive choroidal detachment was evident in close 
contact with the lens, which necessitated an emergency sclerotomy with reconstruction of 
the anterior chamber. Four months later, the eye proceeded to phthisis bulbi. Five months after 
the injection, the patient complained of mild pain, photophobia, and visual acuity deterioration 
from the fellow eye. The diagnosis of sympathetic ophthalmia was suggested and treated with 
intravitreal injections of triamcinolone acetonide every three months with good response, compli-
cated by elevation of intraocular pressure which we managed with Ahmet valve implantation. 
Conclusion: Serious ocular complications after intravitreal of Avastin® can not be excluded, 
including massive choroidal hemorrhage and sympathetic ophthalmia of the fellow eye. 
Keywords: Avastin® complication, intravitreal injection, choroidal detachment, Phthisis bulbi, 
sympathetic ophthalmia
Introduction
Intravitreal administration of bevacizumab (Avastin®; Genentech, Inc., San Francisco, 
CA), a humanized monoclonal antibody to vascular endothelial growth factor (VEGF), 
has been reported to help in age-related macular degeneration (AMD)1–3 and in regres-
sion of retinal and iris neovascularization.4,5
Case report
A 75-year-old male without history of ocular surgical intervention had an intravitreal 
injection of 1.25 mg bevacizumab (Avastin®) in the right eye (RE) because of exuda-
tive age-related macular degeneration. The patient had mild hypertension and was on 
metoprolol 50 mg tablets (Lopressor®) bid. The patient did not have bleeding tendency, 
history of liver disease, and was not on anticoagulants.
Ten days after intravitreal injection, he manifested acute loss of vision with 
excruciating pain in the RE and he was admitted to our hospital. On presentation, his 
best-corrected visual acuity was no light perception (NLP) in the RE and 3/10 from 
the left eye (LE). The patient had an unbearable continuous excruciated pain in his 
RE. The conjunctiva was congestive, the cornea edematous, and the anterior chamber 
(AC) was collapsed (Figure 1A). An extensive choroidal detachment was evident in Clinical Ophthalmology 2009:3 458
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close contact with the lens (Figures 1B, 1C).The intraocular 
pressure in the patient’s RE was 55 mmHg, while he was on 
oral carbonic anhydrease inhibitor, drops of Xalatan® once 
daily (latanoprost), and Cosopt® bid (fixed combination 
of dorsolamide hydrochloride and timolol maleate). The 
intraocular pressure of the patient’s LE was 14 mmHg. The 
fundus examination of the LE revealed extensive confluent 
soft drusen at the posterior pole.
The intravenous administration of carbonic anhydrease 
inhibitor and hyperosmotic agent failed to reduce the intra-
ocular pressure and to alleviate the pain. An emergency 
sclerotomy with reconstruction of the AC with viscoelastic 
was performed two days later. Two months later, the eye was 
painless, hypotonous, and there was detachment, residual 
subretinal fibrosis, and hemorrhage (Figure 1D). Four months 
later, the RE proceeded to phthisis bulbi (Figure 1E).
Five months after the injection, the patient complained 
of mild pain, photophobia, and visual acuity deteriora-
tion in his fellow eye. On presentation his best-corrected 
visual acuity in the LE was 1/20, and the fundus examina-
tion revealed extensive confluent drusen at the posterior 
pole with edema of the optic disc and flare and cells in the 
vireous. A fundus photograph (Figure 2A) and fluorescein 
angiography were inconclusive due to dense cataract 
(Figures 2B, 2C). The diagnosis of sympathetic ophthalmia 
was suggested. Since the patient had a subtotal gastrectomy 
for uncontrollable bleeding from peptic ulcer 15 years ago, 
activated by an excessive salicylates intake, we opted for only 
topical and parabulbar steroids. Ten days later, the patient 
experienced significant visual improvement. Three months 
later, his best-corrected visual acuity in the left eye was 2/10 
while he still was under treatment.
Finally the patient overcame his fears and let us to pro-
ceed with intravitreal injections of triamcinolone acetonide 
every three months with a good response6,7 complicated by 
an elevation of intraocular pressure, which we managed with 
an Ahmet valve implantation. Now, 11 months later, his best 
corrected vision is 1/10.
Discussion
Systemic administration of bevacizumab causes serious 
and, in some cases, fatal adverse reactions. Hemoptysis has 
occurred in patients with non-small cell lung cancer treated 
with chemotherapy combined with Avastin®.8 In a small 
study, the incidence of serious or fatal hemoptysis was 31% 
in patients with squamous histology and 4% in patients 
with adenocarcinoma receiving Avastin® compared to cases 
treated with chemotherapy alone. It is advised that patients 
with a history of recent hemoptysis should not receive 
Avastin®.8
When data were pooled from two randomized phase II 
studies utilizing bevacizumab with 5-FU/leucovorin, and 
Figure 1 A) right eye on presentation.  The conjunctiva was congestive, the cornea edematous, and the anterior chamber collapsed. B) extensive choroidal detachment was evident 
in close contact with the lens. C) extensive choroidal detachment revealed by a B-scan image. D) B-scan image two months later. E) Four months later, right eye phthisis bulbi.Clinical Ophthalmology 2009:3
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also in a third treatment arm of bevacizumab/5-FU/LV 
of a randomized phase III study, a few toxicities were 
uniformly encountered in all of the above studies.9 The 
reported toxicities were grade 3 (medically manageable) 
hypertension (3%–16%), hemorrhage (2%–9.3%), gastro-
intestinal perforation (1.5%), arterial thromboembolism 
(3.8%), wound-healing problems (1%–2%), and proteinuria 
(1%–2%).9
The reported ocular complications of intravitreal 
injection for ARMD so far, are tears of retinal pigment 
epithelium10–13 and complications related to the injection 
site mainly, as conjunctival hyperemia and subconjunctival 
hemorrhage.14
Our case demonstrates a serious ocular complication 
initiated ten days after intravitreal administration of Avastin® 
in a patient with exudative AMD.
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Figure 2 Dense cataract obscures details. A) Color fundus photograph of the left eye 
five months after the intavitreal injection of Avastin® in the right eye. B, C) Fluorescein 
angiography five months after the intavitreal injection of Avastin® in the right eye.